Analysts at CLSA expect the company to remain acquisitive towards specialty products.
Terming the new year to be a make-or-break one for Sun Pharma, CLSA believes that specialty pipeline will be a key focus area.
In India, it said, Sun Pharma would aim to outperform industry growth after a weak CY2018.
Analysts at the firm expect the company to remain acquisitive towards specialty products.
Stock valuation is attractive and stronger specialty portfolio ramp up could drive re-rating.
The global research firm also believes that Sun’s PE premium valuations to peers could be impacted till corporate governance issues resolved.
It is also betting on improving fundamentals in the US and no. 1 India rank.
The brokerage has a buy call on the stock with a target at Rs 560.Disclaimer: The above report is compiled from information available on public platforms. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.